Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3532-3541

  Rabaaoui, Samira ^a   Zouhiri, Fatima ^b   Lançon, Agnès ^a   Leh, Hervé ^b   D'Angelo, Jean ^c   Wattel, Eric ^a,d,e  

^a UNIVERSITÉ LYON 1   (France)

^b BioAlliance Pharma   (France)

^c CNRS   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTIVIRUS AGENT; DIKETO ACID; FZ 123; FZ 149; FZ 41; FZ 55; INTEGRASE INHIBITOR; KH 151; KH 161; KH 211; KH 227; L 839616; QUINOLINE DERIVATIVE; STYRYLQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROVIRUS; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HIV INTEGRASE INHIBITORS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTEGRASE INHIBITORS; KETONES; PROVIRUSES; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 54049149799     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01361-07     Document Type: Article

References (50)

1. Balakrishnan, M., and C. B. Jonsson. 1997. Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. J. Virol. 71:1025-1035.
2. Balestrieri, E., G. Forte, C. Matteucci, A. Mastino, and B. Macchi. 2002. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob. Agents Chemother. 46:3080-3083.
3. Bazarbachi, A., D. Ghez, Y. Lepelletier, R. Nasr, H. de The, M. E. El-Sabban, and O. Hermine. 2004. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 5:664-672.
4. Bazarbachi, A., R. Nasr, M. E. El-Sabban, A. Mahe, R. Mahieux, A. Gessain, N. Darwiche, G. Dbaibo, J. Kersual, Y. Zermati, L. Dianoux, M. K. Chelbi-Alix, H. de The, and O. Hermine. 2000. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 14:716-721.
5. Benard, C., F. Zouhiri, M. Normand-Bayle, M. Danet, D. Desmaele, H. Leh, J. F. Mouscadet, G. Mbemba, C. M. Thomas, S. Bonnenfant, M. Le Bret, and J. d'Angelo. 2004. Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity. Bioorg. Med. Chem. Lett. 14:2473-2476.
6. Bonnenfant, S., C. M. Thomas, C. Vita, F. Subra, E. Deprez, F. Zouhiri, D. Desmaele, J. D'Angelo, J. F. Mouscadet, and H. Leh. 2004. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J. Virol. 78:5728-5736.
7. Cavrois, M., S. Wain-Hobson, and E. Wattel. 1995. Stochastic events in the amplification of HTLV-I integration sites by linker-mediated PCR. Res. Virol. 146:179-184.
8. Chi, G., V. Nair, E. Semenova, and Y. Pommier. 2007. A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity. Bioorg. Med. Chem. Lett. 17:1266-1269.
9. Chow, S. A., K. A. Vincent, V. Ellison, and P. O. Brown. 1992. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 255:723-726.
10. Courcot, B., D. Firley, B. Fraisse, P. Becker, J. M. Gillet, P. Pattison, D. Chernyshov, M. Sghaier, F. Zouhiri, D. Desmaele, J. d'Angelo, F. Bonhomme, S. Geiger, and N. E. Ghermani. 2007. Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors. J. Phys. Chem. B 111:6042-6050.
11. Craigie, R., T. Fujiwara, and F. Bushman. 1990. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 62:829-837.
12. Czyz, A., K. A. Stillmock, D. J. Hazuda, and W. S. Reznikoff. 2007. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors. Biochemistry 46:10776-10789.
13. d'Angelo, J., J. F. Mouscadet, D. Desmaele, F. Zouhiri, and H. Leh. 2001. HIV-1 integrase: the next target for AIDS therapy? Pathol. Biol. (Paris) 49:237-246.
14. Datta, A., M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot. 2006. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108:1021-1029.
15. Dayam, R., J. Deng, and N. Neamati. 2006. HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev. 26:271-309.
16. Deprez, E., S. Barbe, M. Kolaski, H. Leh, F. Zouhiri, C. Auclair, J. C. Brochon, M. Le Bret, and J. F. Mouscadet. 2004. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 65:85-98.
17. Dewan, M. Z., J. N. Uchihara, K. Terashima, M. Honda, T. Sata, M. Ito, N. Fujii, K. Uozumi, K. Tsukasaki, M. Tomonaga, Y. Kubuki, A. Okayama, M. Toi, N. Mori, and N. Yamamoto. 2006. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 107:716-724.
18. Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221.
19. Espeseth, A. S., P. Felock, A. Wolfe, M. Witmer, J. Grobler, N. Anthony, M. Egbertson, J. Y. Melamed, S. Young, T. Hamill, J. L. Cole, and D. J. Hazuda. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA 97:11244-11249.
20. Firley, D., B. Courcot, J. M. Gillet, B. Fraisse, F. Zouhiri, D. Desmaele, J. d'Angelo, and N. E. Ghermani. 2006. Experimental/theoretical electrostatic properties of a styrylquinoline-type HIV-1 integrase inhibitor and its progenitors. J. Phys. Chem. B 110:537-547.
21. Garcia-Lerma, J. G., S. Nidtha, and W. Heneine. 2001. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J. Infect. Dis. 184:507-510.
22. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
23. Grobler, J. A., K. Stillmock, B. Hu, M. Witmer, P. Felock, A. S. Espeseth, A. Wolfe, M. Egbertson, M. Bourgeois, J. Melamed, J. S. Wai, S. Young, J. Vacca, and D. J. Hazuda. 2002. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 99:6661-6666.
24. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
25. Hermine, O., D. Bouscary, A. Gessain, P. Turlure, V. Leblond, N. Franck, A. Buzyn-Veil, B. Rio, E. Macintyre, F. Dreyfus, et al. 1995. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332:1749-1751.
26. Igakura, T., J. C. Stinchcombe, P. K. Goon, G. P. Taylor, J. N. Weber, G. M. Griffiths, Y. Tanaka, M. Osame, and C. R. Bangham. 2003. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299:1713-1716.
27. Jonsson, C. B., G. A. Donzella, E. Gaucan, C. M. Smith, and M. J. Roth. 1996. Functional domains of Moloney murine leukemia virus integrase defined by mutation and complementation analysis. J. Virol. 70:4585-4597.
28. Katz, R. A., G. Merkel, J. Kulkosky, J. Leis, and A. M. Skalka. 1990. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell 63:87-95.
29. Kazanji, M., A. Ureta-Vidal, S. Ozden, F. Tangy, B. de Thoisy, L. Fiette, A. Talarmin, A. Gessain, and G. de The. 2000. Lymphoid organs as a major reservoir for human T-cell leukemia virus type 1 in experimentally infected squirrel monkeys (Saimiri sciureus): provirus expression, persistence, and humoral and cellular immune responses. J. Virol. 74:4860-4867.
30. Kitamura, K., D. L. Rudolph, C. Goldsmith, T. M. Folks, and R. B. Lal. 1993. Isolation, characterization, and transmission of human T-lymphotropic virus types I and II in culture. Curr. Microbiol. 27:355-360.
31. Leclercq, I., F. Mortreux, A. Gabet, C. B. Jonsson, and E. Wattel. 2000. Basis of HTLV-1 target site selection. AIDS Res. Hum. Retrovir. 16:1653-1659.
32. Machuca, A., B. Rodes, and V. Soriano. 2001. The effect of antiretroviral therapy on HTLV infection. Virus Res. 78:93-100.
33. Mekouar, K., J. F. Mouscadet, D. Desmaele, F. Subra, H. Leh, D. Savoure, C. Auclair, and J. d'Angelo. 1998. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 41:2846-2857.
34. Miyoshi, I., I. Kubonishi, S. Yoshimoto, T. Akagi, Y. Ohtsuki, Y. Shiraishi, K. Nagata, and Y. Hinuma. 1981. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294:770-771.
35. Mizuuchi, K. 1992. Polynucleotidyl transfer reactions in transpositional DNA recombination. J. Biol. Chem. 267:21273-21276.
36. Mortreux, F., A. S. Gabet, and E. Wattel. 2003. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 17:26-38.
37. Mortreux, F., M. Kazanji, A. S. Gabet, B. de Thoisy, and E. Wattel. 2001. Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus). J. Virol. 75:1083-1089.
38. Moules, V., C. Pomier, D. Sibon, A. S. Gabet, M. Reichert, P. Kerkhofs, L. Willems, F. Mortreux, and E. Wattel. 2005. Fate of premalignant clones during the asymptomatic phase preceding lymphoid malignancy. Cancer Res. 65:1234-1243.
39. Mousnier, A., H. Leh, J. F. Mouscadet, and C. Dargemont. 2004. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 66:783-788.
40. Normand-Bayle, M., C. Benard, F. Zouhiri, J. F. Mouscadet, H. Leh, C. M. Thomas, G. Mbemba, D. Desmaele, and J. d'Angelo. 2005. New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity. Bioorg. Med. Chem. Lett. 15:4019-4022.
41. Ouali, M., C. Laboulais, H. Leh, D. Gill, D. Desmaele, K. Mekouar, F. Zouhiri, J. d'Angelo, C. Auclair, J. F. Mouscadet, and M. Le Bret. 2000. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J. Med. Chem. 43:1949-1957.
42. Ouali, M., C. Laboulais, H. Leh, D. Gill, E. Xhuvani, F. Zouhiri, D. Desmaele, J. d'Angelo, C. Auclair, J. F. Mouscadet, and M. Le Bret. 2000. Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core. Acta Biochim. Pol. 47:11-22.
43. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
44. Pommier, Y., and N. Neamati. 1999. Inhibitors of human immunodeficiency virus integrase. Adv. Virus Res. 52:427-458.
45. Pruss, D., R. Reeves, F. Bushman, and A. Wolffe. 1994. The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J. Biol. Chem. 40:25031-25041.
46. Shimura, K., E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, Y. Watanabe, Y. Ohata, S. Doi, M. Sato, M. Kano, S. Ikeda, and M. Matsuoka. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
47. Sibon, D., A. S. Gabet, M. Zandecki, C. Pinatel, J. Thete, M. H. Delfau-Larue, S. Rabaaoui, A. Gessain, O. Gout, S. Jacobson, F. Mortreux, and E. Wattel. 2006. HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J. Clin. Investig. 116:974-983.
48. Yoder, K. E., and F. D. Bushman. 2000. Repair of gaps in retroviral DNA integration intermediates. J. Virol. 74:11191-11200.
49. Zhang, J., E. Balestrieri, S. Grelli, C. Matteucci, V. Pagnini, C. D'Agostini, A. Mastino, and B. Macchi. 2001. Efficacy of 3′-azido 3′deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. Virus Res. 78:67-78.
50. Zouhiri, F., J. F. Mouscadet, K. Mekouar, D. Desmaele, D. Savoure, H. Leh, F. Subra, M. Le Bret, C. Auclair, and J. d'Angelo. 2000. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J. Med. Chem. 43:1533-1540.